Last reviewed · How we verify
Ewing's sarcoma — Treatment Landscape & Competitive Intelligence
3 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Temodar | temozolomide | Merck & Co. | Alkylating Drug [EPC] | 1999-01-01 | ||
| Cosmegen | DACTINOMYCIN | Recordati | Actinomycin [EPC] | DNA | 1964-01-01 | |
| Temodal | Temodal | Armando Santoro, MD |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Armando Santoro, MD · 1 drug in Ewing's sarcoma
- Merck & Co. · 1 drug in Ewing's sarcoma
- Recordati · 1 drug in Ewing's sarcoma
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Ewing's sarcoma:
- Ewing's sarcoma treatment updates — RSS
- Ewing's sarcoma treatment updates — Atom
- Ewing's sarcoma treatment updates — JSON
Cite this brief
Drug Landscape (2026). Ewing's sarcoma — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/ewing-s-sarcoma. Accessed 2026-06-10.
Related
- Ewing's sarcoma full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing